Skip to main content
. Author manuscript; available in PMC: 2022 May 21.
Published in final edited form as: Neuroscience. 2021 Apr 6;463:143–158. doi: 10.1016/j.neuroscience.2021.03.029

Figure 3: MDZ + 30 mg/kg retigabine retains its antiseizure efficacy at a treatment delay of 40-min post-SE onset.

Figure 3:

(A) Representative EEG traces from rats that received MDZ + PEG200 and MDZ + 30 mg/kg retigabine. Purple line marks time of treatment, which occurred 40-min after SE onset. Inset boxes show representative expanded EEG traces from each treatment group at: time of treatment (Tx), 1 hr post-treatment, and 4 hr post-treatment. (B) Latency to SE termination (min) for each treatment group. Data points at the 240-min mark represent rats that failed to demonstrate SE termination. (C) Change in EEG gamma power relative to baseline for each treatment group. Significant differences at each hour time point are noted on the y axis. (D) Change in mean spike frequency relative to baseline for each treatment group. Significant differences at each hour time point are noted on the y axis. (E) Average Fluoro-Jade B count for each brain region of interest from each treatment group. (F) Representative Fluoro-Jade B staining from the piriform cortex of each treatment group. Scale bar represents 50 μm. Significance values: *p<0.05 MDZ + 30 mg/kg retigabine vs. MDZ + PEG200, Student’s t-test. EEG data represents average ± 95% confidence intervals.